Medical Devices

Financial experts from Bank of America anticipate a promising scenario for mergers and acquisitions within the medical technology sector by 2025. According to Travis Steed, Stephanie Piazzola, Craig Bijou, and Enjia Cao, the year 2024 represented a “typical year” in […]

Valencia, California-based SetPoint Medical announced today that they have formally lodged an application for premarket approval (PMA) with the FDA for their neuroimmune modulation device. The company is pioneering this technology as a potential novel treatment option for individuals suffering

AngioDynamics recently declared the achievement of FDA 510(k) clearance for its NanoKnife System, intended for prostate tissue ablation in individuals with moderate-risk prostate cancer. The approval is a result of the concluding phase of the pivotal PRESERVE clinical trial, which

InspireMD has announced the commencement of patient enrollment for its pivotal CGUARDIANS II study. This research will explore the efficacy of the CGuard Prime Carotid Stent System during trans carotid artery revascularization (TCAR) procedures. Dr. Patrick Muck, the co-principal investigator,

Anteris Technologies has revealed its intention to launch an initial public offering (IPO) in the United States. The company plans to utilize proceeds from the IPO to enhance the progression of its DurAVR transcatheter heart valve innovation. The offering includes

Stereotaxis (NYSE:STXS) announced the approval of its Magbot magnetic navigation ablation catheter by Chinese regulatory authorities today. This approval comes shortly after the company’s Genesis robotic magnetic navigation (RNM) system received clearance from China’s National Medical Products Administration. Headquartered in

Vicarious Surgical (NYSE:RBOT) recently disclosed that William Kelly, their Chief Financial Officer, has decided to leave the organization in pursuit of other career paths. Kelly began his tenure at the Waltham, Massachusetts-based firm in January 2021, and is slated to

On [today’s date], Cala Health revealed that it has secured a $50 million growth financing round to enhance its TAPS therapy. Leading the investment were Vertex Growth Fund and Nexus NeuroTech Ventures. All prior investors, including Action Potential, Johnson &

As the curtain falls on 2024, there’s been a surge in job reductions within the medtech sector. **Sean Whooley, Associate Editor, and Chris Newmarker, Editor-in-Chief** The medical device sector is concluding the year with an increase in job cuts. Reports

Lungpacer Medical announced it has obtained premarket approval from the FDA for their leading AeroPace neurostimulation device. The AeroPace system utilizes neurostimulation through an electrode-equipped cardiovascular catheter and a software-driven management system. It periodically stimulates the phrenic nerve via the